Professor Alan Boyd
Professor Alan Boyd began his 35 years’ pharmaceutical career with Glaxo Group Research Ltd. From 1988 he led ICI’s cardiovascular medical research team, later assuming the role of Director of Clinical and Medical Affairs at ICI Pharma, Canada. In 1999, after four years as Head of Medical Research for Zeneca Pharmaceuticals, he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for delivering the majority of key development milestones that have shaped the company. In particular, he led the development of their gene-based medicines portfolio.
In April 2005, he left to set up Boyd Consultants. The focus of which is to aid and support early stage life-science based companies of the sort of which Ark had its origins. His clients now include many companies in Europe, North America and Japan who are devoted to the development of medical drug products, devices and in vitro devices.
A graduate in Biochemistry and Medicine from the University of Birmingham, UK, Professor Boyd is also a Fellow and immediate Past President of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He was previously Chair of the Specialist Advisory Committee in Pharmaceutical Medicine at The Royal College of Physicians, United Kingdom.
In November 2009 he was appointed an Honorary Professor at the College of Medical and Dental Sciences at the University of Birmingham Medical School, in recognition of his expertise in medicines development. In October 2014, he was elected as a fellow of the Royal Society of Biology and in April 2018 he was elected as a fellow of the Royal College of Physicians, London.
Professor Boyd also received the ‘Outstanding Contribution Award’ at the 15th Annual Bionow Awards ceremony in November 2016. This award was given in recognition of his significant contribution to the development of medicines and the speciality of Pharmaceutical Medicine as an industrialist, an educator and an inspirational leader. Most recently, his company received the Queen’s Award for Enterprise, that was made in recognition of the company’s work in supporting the development of cell and gene therapies, as well as providing the expertise and skills necessary for the international development of other pharmaceutical and biotechnology products.
Professor Alan Boyd BSc MB ChB FRSB FRCP FFPM